Is there any relationship between photodynamic therapy for exudative age-related macular degeneration and choroidal neovascularization recurrence? A rationale for combined treatments

European Journal of Ophthalmology

Volumn 16, Issue 5, 2006, Pages 686-694

  Piermarocchi, Stefano ^a   Sartore, M ^a   Lo Giudice, G ^a   Monterosso, G ^a   Pilotto, E ^a   Segato, T ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Age related macular degeneration; Choroidal neovascularization; Choroidal neovascularization recurrence; Photodynamic

Indexed keywords

FLUORESCEIN; INDOCYANINE GREEN;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RECURRENT DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RISK FACTOR; SUBRETINAL NEOVASCULARIZATION;

EID: 33845286494     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210601600505     Document Type: Article

References (26)

1. Augood CA, Vingerling JR, de Jong PTVM, et al. The European Eye Study, EUREYE. Prevalence of age-related maculopathy in older Europeans. Arch Ophthalmol 2006; 124: 529-35.
2. Sunness JS, Gonzalez-Baron J, Bressler NM, Hawkins B, Applegate CA. The development of choroidal neovascularization in eyes with the geographic atrophy form of age-related macular degeneration. Ophthalmology 1999; 106: 910-9.
3. Vinding T. Visual impairment of age-related macular degeneration. An epidemiological study of 1000 aged individuals. Acta Ophthalmol (Copenh) 1990; 68: 162-7.
4. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Three-year results from randomized clinical trials. Arch Ophthalmol 1986; 104: 694-701.
5. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Arch Ophthalmol 1991; 109: 1109-14.
6. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1991; 109: 1220-31.
7. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal recurrent neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1991; 109: 1232-41.
8. Blinder KJ, Bradley S, Bressler NM, et al. Treatment of Age-related Macular Degeneration with Photodynamic Therapy study group; Verteporfin in Photodynamic Therapy study group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol 2003; 136: 407-18.
9. Blumenkranz MS, Bressler NM, Bressler SB, et al. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials - TAP Report no. 5. Arch Ophthalmol 2002; 120: 1307-14.
10. Bressler NM, Arnold J, Benchaboune M, et al. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes - TAP report No. 3. Arch Ophthalmol 2002; 20: 1443-54.
11. Bressler NM. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP report 2. Arch Ophthalmol 2001; 119: 198-207.
12. Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 2000; 45: 195-214.
13. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Arch Ophthalmol 1999; 117: 1329-45.
14. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001; 131: 541-60.
15. Isola V, Pece A, Brancato R. Circulatory changes in the choroidal vasculature after verteporfin-based photodynamic therapy for choroidal neovascularization in age-related macular degeneration. Retina 2004; 24: 618-20.
16. Schmidt-Erfurth U, Laqua H, Schlotzer-Schrehard U, Viestenz A, Naumann GO. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol 2002; 120: 835-44.
17. Michels S, Schmidt-Erfurth U. Sequence of early vascular events after photodynamic therapy. Invest Ophthalmol Vis Sci 2003; 44: 2147-54.
18. Piermarocchi S, Lo Giudice G, Sartore M, et al. Photodynamic therapy increases the eligibility for feeder vessel treatment of choroidal neovascularization caused by age-related macular degeneration. Am J Ophthalmol 2002; 133: 572-5.
19. Eter N, Vogel A, Inhetvin-Hutter C, Spitznas M. Short-term reaction of choroidal neovascularization and choriocapillaris to photodynamic therapy in age-related macular degeneration. Eur J Ophthalmol 2003; 13: 687-92.
20. Arroyo JG, Michaud N, Jakobiec FA. Choroidal neovascular membranes treated with photodynamic therapy. Arch Ophthalmol 2003; 121: 898-903.
21. Rudolf M, Michels S, Schlotzer-Schrehardt U, Schmidt-Erfurth U. Expression of angiogenic factors by photodynamic therapy. Klin Monatsbl Augenheilkd 2004; 221: 1026-32.
22. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003; 44: 4473-80.
23. Costa RA, Farah ME, Cardillo JA, Calucci D, Williams GA. Immediate indocyanine green angiography and optical coherence tomography evaluation after photodynamic therapy for subfoveal choroidal neovascularization. Retina 2003; 23: 159-65.
24. Rogers AH, Martidis A, Greenberg PB, Puliafito CA. Optical coherence tomography findings following photodynamic therapy of choroidal neovascularization. Am J Ophthalmol 2002; 134: 566-76.
25. Reinke MH, Canakis C, Husain D, et al. Verteporfin photodynamic therapy retreatment of normal retina and choroids in cynomolgus monkey. Ophthalmology 1999; 106: 1915-23.
26. Postelmans L, Pasteels B, Coquelet P, El Ouardighi H, Verougstraete C, Schmidt-Erfurth U. Severe pigment epithelial alterations in the treatment area following photodynamic therapy for classic choroidal neovascularization in young females. Am J Ophthalmol 2004; 138: 803-8.